<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>systemic inflammation indicators &#8211; Science</title>
	<atom:link href="https://scienmag.com/tag/systemic-inflammation-indicators/feed/" rel="self" type="application/rss+xml" />
	<link>https://scienmag.com</link>
	<description></description>
	<lastBuildDate>Tue, 13 Jan 2026 16:30:03 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1</generator>

<image>
	<url>https://scienmag.com/wp-content/uploads/2024/07/cropped-scienmag_ico-32x32.jpg</url>
	<title>systemic inflammation indicators &#8211; Science</title>
	<link>https://scienmag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">73899611</site>	<item>
		<title>Blood Ratios Signal H. pylori Gastritis in Kids</title>
		<link>https://scienmag.com/blood-ratios-signal-h-pylori-gastritis-in-kids/</link>
		
		<dc:creator><![CDATA[Kristina Jarvis]]></dc:creator>
		<pubDate>Tue, 13 Jan 2026 16:30:03 +0000</pubDate>
				<category><![CDATA[Technology and Engineering]]></category>
		<category><![CDATA[diagnostic challenges in pediatric populations]]></category>
		<category><![CDATA[early detection of H. pylori infection]]></category>
		<category><![CDATA[Helicobacter pylori gastritis in children]]></category>
		<category><![CDATA[hematological ratios in diagnostics]]></category>
		<category><![CDATA[immune response in pediatric patients]]></category>
		<category><![CDATA[implications of gastritis in children]]></category>
		<category><![CDATA[long-term effects of H. pylori infection]]></category>
		<category><![CDATA[neutrophils-to-lymphocytes ratio study]]></category>
		<category><![CDATA[non-invasive biomarkers for gastritis]]></category>
		<category><![CDATA[pediatric gastroenterology]]></category>
		<category><![CDATA[platelets-to-lymphocytes ratio significance]]></category>
		<category><![CDATA[systemic inflammation indicators]]></category>
		<guid isPermaLink="false">https://scienmag.com/blood-ratios-signal-h-pylori-gastritis-in-kids/</guid>

					<description><![CDATA[In a groundbreaking study poised to reshape the diagnostic landscape of pediatric gastroenterology, researchers have unveiled compelling evidence linking specific hematological ratios to Helicobacter pylori-associated gastritis in children. This development promises to enhance early detection efforts, potentially safeguarding young patients from the long-term sequelae of this pervasive gastric infection. Helicobacter pylori, a gram-negative bacterium, colonizes [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>In a groundbreaking study poised to reshape the diagnostic landscape of pediatric gastroenterology, researchers have unveiled compelling evidence linking specific hematological ratios to Helicobacter pylori-associated gastritis in children. This development promises to enhance early detection efforts, potentially safeguarding young patients from the long-term sequelae of this pervasive gastric infection.</p>
<p>Helicobacter pylori, a gram-negative bacterium, colonizes the stomach lining and is implicated in a spectrum of gastrointestinal disorders. While its role in adult gastritis and gastric cancer is well-documented, its manifestation and diagnosis in pediatric populations present unique challenges. Traditional diagnostic approaches, such as endoscopy and biopsy, are invasive and often impractical for children, emphasizing the urgent need for reliable, non-invasive biomarkers.</p>
<p>The study meticulously investigates two hematological parameters: the platelets-to-lymphocytes ratio (PLR) and the neutrophils-to-lymphocytes ratio (NLR). These indices, derived from complete blood counts, have emerged as reflective markers of systemic inflammation and immune response dynamics. Platelets, primarily known for hemostasis, also participate in inflammatory pathways, while neutrophils and lymphocytes orchestrate innate and adaptive immune responses, respectively.</p>
<p>By analyzing blood samples from a cohort of children diagnosed with H. pylori-induced gastritis, the researchers observed a consistent elevation in both PLR and NLR compared to age-matched healthy controls. This elevation underscores an intricate interplay between the pathogen-induced inflammatory milieu and the host’s immunological adjustments. Notably, these ratios act as sensitive barometers, capturing subclinical inflammation that might elude conventional clinical assessment.</p>
<p>The mechanistic underpinnings linking H. pylori infection to alterations in these blood parameters reside in the bacterium’s ability to incite a chronic inflammatory response. This inflammation triggers an increase in neutrophil recruitment as part of the innate immune defense, while concomitant lymphocyte modulation reflects an adaptive immune attempt to contain and eradicate the infection. Platelet activation further complements this inflammatory cascade, possibly exacerbating mucosal injury and perpetuating gastric inflammation.</p>
<p>Clinically, the utilization of PLR and NLR as diagnostic tools heralds a paradigm shift. Their calculation from routine blood tests circumvents the need for invasive procedures, catering to pediatric patients’ unique needs. Moreover, given the global prevalence of H. pylori and its profound health implications, these readily accessible markers could facilitate widespread screening and timely intervention.</p>
<p>The study&#8217;s robust statistical analysis affirms that both ratios possess significant sensitivity and specificity in distinguishing H. pylori gastritis from other non-infectious gastric conditions. These findings invite consideration of integrating hematological ratio assessment into diagnostic algorithms, complementing existing serological and urea breath tests.</p>
<p>Beyond diagnosis, these markers may provide prognostic insights. Persistent elevation of PLR and NLR could indicate sustained inflammation and potentially forecast complications such as gastric atrophy or neoplasia, highlighting pathways for therapeutic monitoring. Future longitudinal studies could elucidate their utility in tracking treatment response and disease remission.</p>
<p>This research also raises intriguing questions about the role of systemic inflammation in pediatric gastric pathology. The systemic nature of these hematological changes reflects that H. pylori infection is not merely a localized gastric condition but one with wider immunological ramifications. Such insights could expand therapeutic strategies, incorporating anti-inflammatory and immunomodulatory interventions.</p>
<p>Furthermore, the accessibility and cost-effectiveness of measuring PLR and NLR align well with resource-limited settings where endoscopic services are scarce. Widespread adoption could democratize diagnostic capabilities, reducing disparities in pediatric healthcare delivery globally.</p>
<p>The authors emphasize the importance of standardized thresholds for these ratios, accounting for age-related hematological variations inherent to pediatric populations. Harmonizing these values will be crucial for clinical applicability across diverse demographics and healthcare systems.</p>
<p>While promising, these findings necessitate cautious interpretation. Confounding factors such as concurrent infections, hematological disorders, or systemic inflammatory conditions can influence PLR and NLR, mandating comprehensive clinical correlation. Hence, these markers should augment, not replace, existing diagnostic modalities.</p>
<p>The scientific community has lauded the study’s methodical approach, encompassing rigorous patient selection, control matching, and detailed immunological profiling. This comprehensive methodology lends credence to the hypothesis that PLR and NLR serve as “canaries in the mine,” heralding gastric inflammation before overt clinical manifestations.</p>
<p>Looking ahead, interdisciplinary collaboration integrating pediatric gastroenterologists, immunologists, and hematologists will be pivotal to refine and validate these biomarkers. Such collaborative efforts could pioneer personalized medicine approaches, tailoring interventions based on individual inflammatory profiles.</p>
<p>In the broader context, this research echoes the growing recognition of hematological parameters as windows into systemic diseases beyond traditional confines. Their application spans oncology, cardiology, and infectious diseases, signifying an evolving paradigm in biomarker science.</p>
<p>Ultimately, the study by Elsaadany et al. represents a beacon of progress in pediatric healthcare, harnessing simple yet powerful tools to confront a complex infectious challenge. By illuminating the diagnostic potential of PLR and NLR, this work charts a course toward earlier detection, improved outcomes, and a deeper understanding of H. pylori-associated gastric pathology in children.</p>
<p>Subject of Research: Pediatric Helicobacter pylori-associated gastritis and the diagnostic potential of hematological ratios.</p>
<p>Article Title: Platelets/lymphocytes ratio and neutrophils/lymphocytes ratio in children with H. pylori associated gastritis: a canary in the mine?</p>
<p>Article References: Elsaadany, E., El Amrousy, D., Qassem, S.S. et al. Platelets/lymphocytes ratio and neutrophils/lymphocytes ratio in children with H. pylori associated gastritis: a canary in the mine?. Pediatr Res (2026). https://doi.org/10.1038/s41390-025-04727-1</p>
<p>Image Credits: AI Generated</p>
<p>DOI: 13 January 2026</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">125962</post-id>	</item>
		<item>
		<title>Inflammation Biomarkers Signal High Lung Tumor Mutations</title>
		<link>https://scienmag.com/inflammation-biomarkers-signal-high-lung-tumor-mutations/</link>
		
		<dc:creator><![CDATA[Nathaniel Bowman]]></dc:creator>
		<pubDate>Thu, 09 Oct 2025 15:34:02 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[genomic profiling in lung cancer]]></category>
		<category><![CDATA[high tumor mutation burden identification]]></category>
		<category><![CDATA[immunotherapy efficacy indicators]]></category>
		<category><![CDATA[innovative cancer research breakthroughs]]></category>
		<category><![CDATA[lung adenocarcinoma research]]></category>
		<category><![CDATA[lung cancer biomarkers]]></category>
		<category><![CDATA[non-small cell lung cancer treatment]]></category>
		<category><![CDATA[personalized medicine in oncology]]></category>
		<category><![CDATA[predictive biomarkers for cancer therapy]]></category>
		<category><![CDATA[systemic inflammation indicators]]></category>
		<category><![CDATA[tumor mutation burden assessment]]></category>
		<category><![CDATA[whole-exome sequencing limitations]]></category>
		<guid isPermaLink="false">https://scienmag.com/inflammation-biomarkers-signal-high-lung-tumor-mutations/</guid>

					<description><![CDATA[In an innovative breakthrough study published in BMC Cancer, researchers have unveiled that systemic inflammation biomarkers may hold the key to identifying high tumor mutation burden (TMB) in lung adenocarcinoma patients. This revelation stands to revolutionize the way clinicians approach the assessment of TMB, a crucial biomarker for immunotherapy efficacy in non-small cell lung cancer [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>In an innovative breakthrough study published in <em>BMC Cancer</em>, researchers have unveiled that systemic inflammation biomarkers may hold the key to identifying high tumor mutation burden (TMB) in lung adenocarcinoma patients. This revelation stands to revolutionize the way clinicians approach the assessment of TMB, a crucial biomarker for immunotherapy efficacy in non-small cell lung cancer (NSCLC). Traditionally, determining TMB has demanded the costly and complex application of whole-exome sequencing (WES), which is often hindered by stringent sample requirements and limited clinical accessibility. This new research offers a promising alternative, focusing on readily measurable systemic inflammation markers to predict TMB status, potentially transforming patient outcomes and personalized medicine practices.</p>
<p>Tumor mutation burden quantifies the number of somatic mutations within a tumor genome and has been firmly established as a predictor of response to immune checkpoint inhibitors, which have gained traction in recent years as a frontline therapeutic modality for NSCLC. However, the reliance on WES to evaluate TMB limits its application, particularly in resource-constrained settings. Motivated to bridge this gap, the study involved comprehensive genomic profiling of tumor tissues and matched peripheral blood samples from 72 lung adenocarcinoma patients. The investigation aimed to delineate mutation landscapes across patients with varying TMB levels, while concurrently profiling systemic inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR).</p>
<p>Through meticulous analysis, the researchers confirmed that missense mutations predominate this cancer subtype, with single nucleotide variants (SNVs) constituting the bulk of these alterations. Among the frequently mutated genes, <em>EGFR</em>, <em>TP53</em>, and <em>TTN</em> emerged as the most prominent players, occurring in 35%, 33%, and 24% of cases respectively. Strikingly, patients with high TMB demonstrated a distinct genetic signature characterized by a higher prevalence of C &gt; A transversions and significantly elevated mutation frequencies in <em>TP53</em> and <em>TTN</em> compared to their low TMB counterparts. These genetic disparities underline the heterogeneity within lung adenocarcinoma and hint at the diverse mutational processes driving tumorigenesis.</p>
<p>Further advancing the understanding of mutational processes, the study identified five de novo mutational signatures, each variably contributing to different TMB strata. This nuance offers vital insight into the etiological factors underpinning genomic instability and mutation accumulation within tumors, which may influence both disease progression and treatment response. By capturing these signatures, researchers can better appreciate the complex interplay between environmental insults, endogenous mechanisms, and immune responses in shaping tumor genomes.</p>
<p>Central to this research was the evaluation of systemic inflammatory markers as surrogate predictors for TMB. Inflammatory mediators circulating in the peripheral blood have garnered attention for their role in cancer biology, particularly due to their interaction with the tumor microenvironment and immune modulation. Employing multivariate generalized linear models, the team uncovered significant associations between elevated NLR and PLR values and high TMB, while lower LMR was also linked to increased mutation burden. These findings suggest that inflammatory status, accessible through routine blood work, might reflect underlying tumor genomic complexity.</p>
<p>The utilization of restricted cubic spline (RCS) plots further illuminated the nature of these relationships, revealing non-linear associations between TMB and the inflammatory indices NLR and PLR. This indicates that the relationship is not simply a direct proportional increase but instead involves more complex dynamics that could reflect threshold effects or nonlinear biological responses. Such insights are critical in refining predictive models and tailoring clinical decision-making strategies.</p>
<p>Recognizing the multifactorial dimensions influencing TMB, the study harnessed the machine learning capabilities of the XGBoost model to evaluate variable importance in TMB prediction. This quantitative assessment underscored the predominant influence of tumor staging (T stage), LMR, and body mass index (BMI) in forecasting mutation burden. Notably, the significant involvement of T stage aligns with the understanding that tumor size and local invasion impact genomic alterations and immune landscape, while systemic factors reflected by BMI and inflammatory profiles play contributory roles.</p>
<p>The integration of systemic inflammatory markers into predictive frameworks for TMB assessment promises tangible benefits in clinical oncology. By circumventing the limitations posed by WES, oncologists may deploy less invasive, cost-effective blood-based biomarkers to identify candidates likely to benefit from immunotherapies, streamlining patient stratification and treatment planning. This approach aligns with the burgeoning paradigm of liquid biopsy, emphasizing minimally invasive diagnostics and real-time monitoring of tumor evolution.</p>
<p>Moreover, the study&#8217;s exploration into the distinct mutational features among Chinese lung adenocarcinoma patients broadens the demographic scope of precision oncology research. Genetic and environmental factors influencing mutation spectra and systemic inflammation may vary across populations, necessitating diverse cohort studies to ensure predictive models are universally applicable or properly tailored to genetic ancestries. The comprehensive analysis here thus contributes valuable genomic and clinical data, enriching the global cancer research repository.</p>
<p>Equally important is the potential impact on health economics and clinical workflows. Should systemic inflammation markers validate as robust predictors of TMB, routine pre-treatment blood tests could reduce diagnostic turnaround times and healthcare expenditure related to genomic testing. This would democratize access to immunotherapy indicators, especially in healthcare settings where WES is not readily available, ultimately enhancing equitable cancer care delivery.</p>
<p>However, challenges remain in fully operationalizing inflammation markers as standalone surrogates for TMB. The inflammatory milieu is influenced by myriad factors including infections, comorbidities, and medications, which could confound biomarker specificity. Therefore, ongoing research will be pivotal in refining algorithms, incorporating additional variables, and validating findings across larger, multi-institutional cohorts to bolster reliability and clinical utility.</p>
<p>The pioneering work by Fang, Li, Xu, and colleagues represents a critical step towards integrating systemic inflammatory biomarkers into the diagnostic toolkit for lung adenocarcinoma. By bridging genomic insights with accessible clinical parameters, this research heralds a new era of precision immuno-oncology, where blood-based inflammation indices complement genetic profiling to identify patients most likely to benefit from novel therapies. As immunotherapy continues to reshape lung cancer treatment paradigms, such advancements portend improved survival outcomes and optimized personalized care in one of the world&#8217;s deadliest malignancies.</p>
<p>In summary, this landmark study elucidates the intricate relationship between systemic inflammation and tumor genomic characteristics, supporting the feasibility of using easily measurable peripheral blood markers to predict high TMB status in lung adenocarcinoma. It underscores the relevance of inflammation as both a biomarker and a biological modulator in cancer progression, offering a cost-effective, minimally invasive approach to patient stratification. The incorporation of machine learning further enhances predictive accuracy, underscoring the power of integrative analytic methods in modern oncology research. Collectively, these findings pave the way for innovative diagnostic strategies and highlight the immense potential of combining genomic and immunological data to personalize cancer treatment.</p>
<hr />
<p><strong>Subject of Research</strong>: Identification of high tumor mutation burden in lung adenocarcinoma using systemic inflammation biomarkers.</p>
<p><strong>Article Title</strong>: Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma.</p>
<p><strong>Article References</strong>:<br />
Fang, J., Li, Q., Xu, N. <em>et al.</em> Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma. <em>BMC Cancer</em> <strong>25</strong>, 1543 (2025). <a href="https://doi.org/10.1186/s12885-025-14894-3">https://doi.org/10.1186/s12885-025-14894-3</a></p>
<p><strong>Image Credits</strong>: Scienmag.com</p>
<p><strong>DOI</strong>: <a href="https://doi.org/10.1186/s12885-025-14894-3">https://doi.org/10.1186/s12885-025-14894-3</a></p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">88267</post-id>	</item>
	</channel>
</rss>
